TransMedics Group (NASDAQ:TMDX) Now Covered by Robert W. Baird

Robert W. Baird started coverage on shares of TransMedics Group (NASDAQ:TMDX) in a report published on Tuesday morning, MarketBeat reports. The firm issued an outperform rating and a $200.00 price objective on the stock.

Other analysts have also issued reports about the stock. Oppenheimer upped their target price on shares of TransMedics Group from $125.00 to $200.00 and gave the stock an outperform rating in a research note on Thursday, August 1st. Stephens increased their price objective on shares of TransMedics Group from $151.00 to $178.00 and gave the company an overweight rating in a research report on Friday, August 2nd. TD Cowen lifted their price objective on shares of TransMedics Group from $130.00 to $175.00 and gave the stock a buy rating in a research report on Friday, June 7th. Canaccord Genuity Group boosted their target price on shares of TransMedics Group from $117.00 to $169.00 and gave the stock a buy rating in a research note on Thursday, August 1st. Finally, Cantor Fitzgerald began coverage on TransMedics Group in a research note on Thursday, June 6th. They issued an overweight rating and a $161.00 price target on the stock. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average target price of $174.30.

TransMedics Group Trading Down 2.5 %

NASDAQ:TMDX opened at $144.56 on Tuesday. TransMedics Group has a 52 week low of $36.42 and a 52 week high of $177.37. The stock’s fifty day moving average is $156.02 and its two-hundred day moving average is $130.77. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. During the same period in the prior year, the firm earned ($0.03) earnings per share. The firm’s revenue was up 117.7% compared to the same quarter last year. On average, equities research analysts predict that TransMedics Group will post 1.23 EPS for the current year.

Insider Activity

In related news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at $9,457,269.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the transaction, the insider now owns 20,843 shares in the company, valued at $3,267,557.11. The disclosure for this sale can be found here. Over the last quarter, insiders sold 61,247 shares of company stock worth $9,650,880. 7.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

Several large investors have recently made changes to their positions in TMDX. Amalgamated Bank grew its stake in shares of TransMedics Group by 6.7% in the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after purchasing an additional 70 shares in the last quarter. Pitcairn Co. lifted its holdings in TransMedics Group by 1.5% in the first quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock worth $398,000 after purchasing an additional 78 shares during the period. Signaturefd LLC grew its position in TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares in the last quarter. Arizona State Retirement System increased its stake in TransMedics Group by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after buying an additional 186 shares during the period. Finally, International Assets Investment Management LLC bought a new stake in shares of TransMedics Group during the 2nd quarter worth about $47,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.